Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04038840 · ClinicalTrials.gov registry record · Phase 1

Imaging Synapses With [11C] UCB-J in the Human Brain

A Phase 1 study of Schizophrenia, sponsored by Davidzon, Guido, M.D..

Recruiting
Registry status
Phase 1
Development phase
60
Enrollment target
2
Study locations

NCT04038840 is a Phase 1 study of Schizophrenia that is actively recruiting participants, run by Davidzon, Guido, M.D.. The registered enrollment target is 60 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04038840, a Phase 1 study of Schizophrenia, is actively recruiting participants, sponsored by Davidzon, Guido, M.D..

RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer \[11C\]UCB-J to test the neural synaptic pruning hypothesis of schizophrenia. This imaging method allows for the quantification of synaptic density in the living human brain and has the unprecedented ability to directly examine the synaptic pathology underlying neuropsychiatric disease. The neural synaptic pruning hypothesis posits that a key pathogenic process of schizophrenia is the over-exuberant elimination of neural synapses during development. The confirmation of reduced synaptic density in schizophrenia as evidenced by \[11C\]UCB-J has the potential to lead to a number of ground-breaking clinical innovations, such as laboratory-based diagnostics and prognostics, and novel, disease-modifying treatments.

Conditions Studied

Schizophrenia

Interventions

  • DRUG [11C]UCB-J radiotracer
  • DEVICE PET-MR

Study Locations (2)

California

  • VA Palo Alto Health Care System - Palo Alto
  • Stanford University - Stanford

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2019-08-01
Est. Completion 2025-12
Phase Phase 1

Sponsor

Davidzon, Guido, M.D.

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04038840

The ClinicalTrials.gov registry entry for NCT04038840 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (73% lower). The listed sponsor is Davidzon, Guido, M.D., which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which [11C]UCB-J radiotracer is the first listed.

NCT04038840 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT04038840 about?

NCT04038840 is a clinical study titled "Imaging Synapses With [11C] UCB-J in the Human Brain". The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer \[11C\]UCB-J to test the neural synaptic pruning hypothesis of schizophrenia. This imaging method allows for the quantification of synaptic density in the living human brain and has the unprecedented ab...

What is the current status of trial NCT04038840?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2019-08-01. Estimated completion is 2025-12.

What conditions does trial NCT04038840 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT04038840?

The interventions under investigation include: [11C]UCB-J radiotracer (DRUG), PET-MR (DEVICE).

Who is sponsoring clinical trial NCT04038840?

This trial is sponsored by Davidzon, Guido, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04038840 being conducted?

This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.